UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
(Exact name of registrant as specified in its charter)
|
|
|
|
|
|
||
|
(State or other jurisdiction of incorporation) |
|
(Commission File Number)
|
|
(IRS Employer Identification No.)
|
||
|
|
|
|
||||
|
(Address of principal executive offices) |
|
(Zip Code) |
||||
Registrant’s telephone number, including area code: (
Not applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
|
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|
|
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|
|
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|
|
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
|
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
|
|
|
The |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).
Emerging Growth Company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
Item 2.02 Results of Operations and Financial Condition
On March 8, 2021, Synlogic, Inc. (the “Company”) announced the promotion of Caroline Kurtz to Chief Development Officer and overall strengthening of leadership. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Item 9.01 Financial Statements and Exhibits.
(d)Exhibits
The following exhibits relating to Item 2.02 shall be deemed to be furnished, and not filed:
|
Exhibit No. |
|
Description |
|
99.1 |
|
|
|
104 |
|
Cover Page Interactive Data File (embedded within the Inline XBRL document) |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
SYNLOGIC, INC. |
||
|
|
|
|
||
|
Date: March 8, 2021 |
|
By: |
|
/s/ Greg Beloff |
|
|
|
Name: |
|
Greg Beloff |
|
|
|
Title: |
|
Interim Chief Financial Officer |
|
|
|
|
|
|
Exhibit 99.1
Synlogic Announces Promotion of Dr. Caroline Kurtz to Chief Development Officer and Strengthening of Leadership Team
CAMBRIDGE, Mass., March 8, 2021 /PRNewswire/ -- Synlogic, Inc. (Nasdaq: SYBX), a clinical stage company bringing the transformative potential of synthetic biology to medicine, today announced the promotion of Dr. Caroline Kurtz to Chief Development Officer. As Chief Development Officer, Dr. Kurtz will be responsible for portfolio strategy, program leadership, and development of Synlogic's portfolio of Synthetic Biotic medicines, including the company's lead assets, SYNB1618 for Phenylketonuria (PKU) and SYNB8802 for Enteric Hyperoxaluria.
"At Synlogic, we are advancing multiple programs rapidly towards meaningful clinical read-outs, executing on our mission of bringing the transformative potential of synthetic biology to medicine," said Aoife Brennan, M.B. Ch.B., Synlogic's President and Chief Executive Officer. "Caroline's track record and experience as a cross-functional leader who has advanced important therapies from pre-clinical to commercial will be critical as our programs continue to advance in the clinic."
"I have a passion for drug development and am excited by the opportunity to advance both our PKU and Enteric Hyperoxaluria candidates towards patients," said Dr. Caroline Kurtz. "Thank you to the Synlogic team members who are working every day to translate our platform into meaningful products for patients. With key data read-outs in PKU and Enteric Hyperoxaluria on the horizon, I am energized by the challenge of bringing these programs into later stages of development while also continuing Synlogic's strong track record of translating our science into compelling clinical candidates."
Dr. Kurtz joined Synlogic in October 2016 and is responsible for program leadership and portfolio planning and progression. With over 25 years of experience in the pharmaceutical industry, Dr. Kurtz has led multiple programs through mid and late-stage clinical development, including as Vice President and GC-C platform lead at Ironwood Pharmaceuticals, where she drove the development of linaclotide (LINZESS®) from pre-IND through NDA approval and life-cycle management. Dr. Kurtz received her Ph.D. in Immunology from Harvard University in the laboratory of Dr. John Weis and carried out post-doctoral training in viral immunology and central nervous system demyelinating diseases in the laboratory of Dr. Robert Fujinami at the University of Utah.
Synlogic also announced the promotion of Daniel Rosan to Senior Vice President and Head of Finance and the appointment of Dr. Jamie Austin to the role of Vice President and Incoming Head of Regulatory Affairs.
Mr. Rosan's responsibilities will include capital markets, investor relations, financial planning and analysis, and accounting. Gregg Beloff will continue as Synlogic's interim Chief Financial Officer. Mr. Rosan brings over 20 years of health care experience in a wide variety of business contexts. Prior to Synlogic, he spent six years at Biogen in roles of increasing responsibility in Finance and Research & Development. Mr. Rosan holds a BA in History from Vassar College and an MBA from Harvard Business School.
Dr. Austin will lead Regulatory Affairs at Synlogic. She has over 15 years of industry experience, including 10 years of consulting and business development. Prior to Synlogic, she has served in regulatory strategy roles at several prominent pharmaceutical and biotech companies including AstraZeneca, AbbVie, and bluebird bio. Dr. Austin received her MS in Bioscience Regulatory Affairs from the Johns Hopkins University and her Ph.D. from the University of Michigan.
About Synlogic
Synlogic™ is bringing the transformative potential of synthetic biology to medicine. With a premiere synthetic biology platform that leverages a reproducible, modular approach to microbial engineering, Synlogic designs Synthetic Biotic medicines that target validated underlying biology to treat disease in new ways. Synlogic's proprietary pipeline includes Synthetic Biotics for the treatment of metabolic disorders including Phenylketonuria (PKU) and Enteric Hyperoxaluria (HOX). The company is also building a portfolio of partner-able assets in immunology and oncology.
Forward-Looking Statements
This press release contains "forward-looking statements" that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, clinical development plans, future financial position, future revenue, projected expenses, prospects, plans and objectives of management are forward-looking statements. In addition, when or if used in this press release, the words "may," "could," "should," "anticipate," "believe," "estimate," "expect," "intend," "plan," "predict" and similar expressions and their variants, as they relate to Synlogic may identify forward-looking statements. Examples of
forward-looking statements, include, but are not limited to, statements regarding the potential of Synlogic's platform to develop therapeutics to address a wide range of diseases including: cancer, inborn errors of metabolism, and inflammatory and immune disorders; the future clinical development of Synthetic Biotic medicines; the approach Synlogic is taking to discover and develop novel therapeutics using synthetic biology; and the expected timing of Synlogic's clinical trials and availability of clinical trial data. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including: the uncertainties inherent in the clinical and preclinical development process; the ability of Synlogic to protect its intellectual property rights; and legislative, regulatory, political and economic developments, as well as
those risks identified under the heading "Risk Factors" in Synlogic's filings with the SEC. The forward-looking statements contained in this press release reflect Synlogic's current views with respect to future events. Synlogic anticipates that subsequent events and developments will cause its views to change. However, while Synlogic may elect to update these forward-looking statements in the future, Synlogic specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Synlogic's view as of any date subsequent to the date hereof.
CONTACT: Media Contact: Lauren Arnold, MacDougall, Phone: 781-235-3060, Email: larnold@macbiocom.com; Investor Contact: Daniel Rosan, Synlogic, Inc., Phone: 617-401-9152, Email: dan.rosan@synlogictx.com